U.S. Food and Drug Administration (FDA) on Wednesday authorized Pfizer Inc’s antiviral COVDI-19 for people ages 12 and older. This marks the first oral and at home treatment for coronavirus.
Earlier Pfizer said Paxlovid drug is 90% effective in preventing hospitalization and deaths in patients, according to the results of its clinical trials.
Pfizer said, it has raised 2022 production projections to 120 million courses of treat from 80 million and was ready to start immediate delivery in the United States.
“Paxlovid’s approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,” said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security, as reported by Reuters.